E. Stroes

2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk.

M. Sabatine, E. Hagström, D. Grobbee, 2019, European heart journal.

High-density lipoprotein cholesterol, high-density lipoprotein particle size, and apolipoprotein A-I: significance for cardiovascular risk: the IDEAL and EPIC-Norfolk studies.

Christina Lindahl, Nicholas J Wareham, Mogens Lytken Larsen, 2008, Journal of the American College of Cardiology.

Coronary artery calcification score as tool for risk assessment among families with premature coronary artery disease.

B. Forster, Y. Arad, M. Groenink, 2016, Atherosclerosis.

Comparison between gradient gel electrophoresis and nuclear magnetic resonance spectroscopy in estimating coronary heart disease risk associated with LDL and HDL particle size.

J. Després, N. Wareham, K. Khaw, 2010, Clinical chemistry.

Improved cardiovascular risk prediction using targeted plasma proteomics in primary prevention

N. Wareham, W. Koenig, K. Khaw, 2020, European heart journal.

Improving cardiovascular disease prevention : from risk assessment to novel therapy

S. Grundy, P. Barter, J. Kastelein, 2009 .

Tryptophan metabolites and incident cardiovascular disease: The EPIC-Norfolk prospective population study.

S. Boekholdt, C. Teunis, Max Nieuwdorp, 2023, Atherosclerosis.

HDL particle size and the risk of coronary heart disease in apparently healthy men and women: the EPIC-Norfolk prospective population study.

J. Després, N. Wareham, K. Khaw, 2009, Atherosclerosis.

Metabolic dyslipidemia and risk of future coronary heart disease in apparently healthy men and women: the EPIC-Norfolk prospective population study.

J. Després, N. Wareham, K. Khaw, 2010, International journal of cardiology.